BioSpace News Archive

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2020 financial results after market close on Thursday, November 26, 2020.

Arena Pharmaceuticals, Inc. announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to purchase an aggregate of 96,025 shares of its common stock and 17,590 inducement restricted stock units.

Showcased at RSNA 2020, the new fluoroscopy systems are designed to deliver rapid access to high-resolution real-time imaging of moving body structures, while reducing patient dose

Advanced Bionics (AB), a global leader in cochlear implant technology, received Health Canada approval and announces it is bringing Marvel hearing technology to Advanced Bionics cochlear implant wearers.

Olympus Begins Accepting Proposals for Newly Launched Investigator Initiated Trials Grants Program

United Spinal Association recently hosted its bi-annual Corporate Advisory Council virtual meeting to address the important role corporate America plays in expanding the rights and inclusion of people with mobility disabilities nationwide.

Fresenius Kabi USA is voluntarily recalling a single lot of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg /mL), 50 mL fill in a 50 mL vial.

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank’s stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Limited (“F-star”)

Mesoblast Limited, announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell product remestemcel-L, with an initial focus on the development of the treatment of acute respiratory distress syndrome, including that associated with COVID-19.

Conformal Medical, Inc., a privately-held medical device company developing next generation left atrial appendage closure (LAAC) technology, today announced the appointment of George Fazio to its board of directors